GNH USA

Europe — EMA

Melfalan Tillomed (Melphalan)

GNH USA supplies Melfalan Tillomed (Melphalan), a alkylating antineoplastic agent for multiple myeloma and other cancers. Request a quote for global supply.

Melphalan

Request sourcing

1
Pack/s

What is Melphalan?

Melphalan, the active ingredient in Melfalan Tillomed, is an alkylating agent (nitrogen mustard) presented as an intravenous solution for intravenous use. It treats multiple myeloma, ovarian cancer, malignant melanoma, testicular cancer, and chronic lymphocytic leukemia in adult patients.

GNH USA supplies Melfalan Tillomed as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

What is Melphalan used for?

Melphalan is used in the treatment of several hematologic and solid malignancies.

Multiple Myeloma: Reduces tumor burden and prolongs survival in eligible patients. Ovarian Cancer: Improves response rates when combined with platinum‑based regimens. Malignant Melanoma: Provides cytoreductive benefit in advanced disease. Testicular Cancer: Used in high‑dose protocols for refractory cases. Chronic Lymphocytic Leukemia: Contributes to disease control in selected treatment plans.

What are the side effects of Melphalan?

Melphalan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting - Fatigue and weakness - Alopecia (hair loss) - Myelosuppression (neutropenia, anemia, thrombocytopenia) - Mucositis and oral ulceration - Diarrhea or constipation

Serious or Rare Side Effects: - Secondary malignancies (e.g., therapy‑related leukemia) - Severe infections due to profound neutropenia - Pulmonary toxicity (interstitial pneumonitis) - Hemorrhagic cystitis - Cardiac toxicity (arrhythmias, myocarditis) - Anaphylactic or severe hypersensitivity reactions

What precautions apply to Melphalan?

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for toxicity.

Renal function: Assess baseline creatinine and adjust dosing if impaired. Hepatic function: Monitor liver enzymes in patients with existing liver disease. Pregnancy: Contraindicated; classified as Category D, avoid use in pregnant women. Infection risk: Monitor complete blood counts and treat febrile neutropenia promptly. Drug interactions: Review concomitant medications for additive myelosuppression. Store at ambient temperature: Keep in original container, protect from light and moisture.

What does Melphalan interact with?

Melphalan can interact with several drugs, requiring careful management.

Major Interactions (Avoid): - Cyclophosphamide: additive bone‑marrow suppression. - Azathioprine: increased risk of severe myelosuppression. - Live vaccines: heightened risk of serious infection.

Moderate Interactions (Monitor Closely): - Allopurinol: may increase melphalan toxicity; monitor renal function. - Aminoglycoside antibiotics: potential nephrotoxicity when combined. - Azole antifungals: may affect melphalan metabolism; adjust monitoring as needed.

Frequently asked questions

What is Melfalan Tillomed used for?+
Melfalan Tillomed contains melphalan, an alkylating chemotherapy agent indicated for the treatment of multiple myeloma, ovarian cancer, malignant melanoma, testicular cancer, and chronic lymphocytic leukemia in adult patients. It is administered as part of multi‑drug regimens to achieve tumor control and improve survival outcomes.
How does melphalan work?+
Melphalan works by forming covalent cross‑links between DNA strands, which blocks DNA replication and transcription. This interference triggers programmed cell death (apoptosis) in rapidly dividing cancer cells, thereby reducing tumor growth and spread.
What is the usual dose of Melfalan Tillomed?+
The specific dose of Melfalan Tillomed is determined by the prescribing oncologist based on the patient’s diagnosis, disease stage, body surface area, renal and hepatic function, and treatment protocol. Dosing is individualized and should follow the clinician’s written order.
Is Melfalan Tillomed safe in pregnancy or breastfeeding?+
Melphalan is classified as Pregnancy Category D, indicating evidence of fetal risk. It is contraindicated in pregnant women and should not be used unless the potential benefit justifies the risk. Breastfeeding is also not recommended, as the drug can be excreted in milk and may harm the infant.
How do I order Melfalan Tillomed from GNH USA?+
To order Melfalan Tillomed, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.
How does melphalan compare with the main alternative drug or class?+
Melphalan belongs to the nitrogen‑mustard alkylating class, similar to cyclophosphamide. Compared with cyclophosphamide, melphalan typically has a higher potency for certain hematologic malignancies but may cause more pronounced myelosuppression. Choice of agent depends on disease type, prior therapy, and individual patient tolerance.
What are the storage and handling requirements for Melfalan Tillomed?+
Melfalan Tillomed should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from direct light, moisture, and extreme temperature fluctuations. Do not freeze. Follow standard aseptic techniques when preparing for intravenous infusion.
How is Melfalan Tillomed administered?+
Melfalan Tillomed is supplied as an intravenous solution and is administered by slow infusion into a peripheral or central vein under the supervision of qualified healthcare professionals. Infusion rates and pre‑medication (e.g., anti‑emetics) are determined by the treating physician based on the specific protocol.
What are the most serious risks to watch for while using Melfalan Tillomed?+
Serious risks include severe myelosuppression leading to infection, anemia, or bleeding; secondary malignancies such as therapy‑related leukemia; pulmonary toxicity (interstitial pneumonitis); hemorrhagic cystitis; and rare but life‑threatening hypersensitivity reactions. Patients should be monitored closely for signs of infection, respiratory symptoms, and urinary irritation.
Who should not use melphalan?+
Melphalan should be avoided in patients with known hypersensitivity to melphalan or other nitrogen‑mustard agents, in pregnant or nursing women, and in individuals with severe bone‑marrow failure or uncontrolled infections. Caution is also advised for patients with significant renal or hepatic impairment, as dose adjustments may be required.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Melphalan
Route
Intravenous Use
Manufacturer
Tillomed Pharma Gmbh
Origin
EU

Related products

Alkeran 2 mg

Alkeran 2 mg

Melphalan · 2 MG

Alkeran
TABLET
ASPEN PHARMACARE CANADA INC.
CANADA
Alkeran

Alkeran

Melphalan

Aspen Pharma Trading Limited
EU
Alkeran

Alkeran

Melphalan

Aspen Pharma Trading Limited
EU
Alkeran

Alkeran

Melphalan

Aspen Pharma Trading Limited
EU